Projects

MVDr. Andrej Barta, PhD.

International

Finished
  • Effects of antioxidants on metabolic syndrome: reactive oxygen species/nitric oxide balance
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2015
  • Effect of natural polyphenols on the development and maintenance of experimental hypertension and remodelling of cardiovascular system
    Program: Inter-institute agreement
    Duration: 1. 10. 2004 – 30. 9. 2013
  • The effect of natural polyphenols on the damage of cardiovascular system and kidney indiced by long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2010
  • Different models of experimental hypertension and their vasoactive systems
    Program: Inter-institute agreement
    Duration: 1. 1. 2005 – 31. 12. 2009
  • The effect of polyphenolic compounds on the prevention and regression of a tissue damage ba long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2004 – 31. 12. 2006

National

Current
  • Identification of stress-induced alterations in expression of NRF2 target genes in rat models of prehypertension: the effect of comorbid hypertriglyceridemia and dimethyl fumarate treatment
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
Finished
  • The effect of aging and hypertension on experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • New perspectives in the treatment of cardiovascular complications associated with COVID-19
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Research of magnetic forms of iron in development of cardiovascular diseases and behavioural disorders
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • The effect of STAT1 and ISG15 inhibitors on biochemical and morphological parameters in experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Cardiovascular Effects of Nanoencapsulated Simvastain and Coenzyme Q10 in Experimental Hyperlipidemia (KANASTA)
    Program: Other projects
    Duration: 27. 11. 2015 – 26. 11. 2018
  • Participation of HMGB1 in experimental myocardial infarction: cardioprotection vs. cardiac depression
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Characterization of cardiovascular and metabolic changes in fructose-induced metabolic syndrome in the rat
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2014
  • The role of nuclear factor kappa B in experimental hypertension
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Effect of antioxidants on blood pressure and manifestation of sympathetic activity in conduit arteries in rats with experimental hypertension
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Modification of hypertrophy and heart failure in the model of continual light-induced hypertension in rats by melatonin and captopril
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2010
  • Long-term low dose L-NAME treatment:Possibility to improve the vascular function in borderline hypertension?
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Mechanism of indapamide effect on the prevention and treatment of experimental hypertension and organ damage
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 0. 0. 0000 – 0. 0. 0000
Employees